By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



1 DNA Way

South San Francisco  California  94080-4990  U.S.A.
Phone: 650-225-1000 Fax: 650-225-6000

Since 2005, Genentech has been expanding its facilities in Oceanside, about 35 miles north of San Diego. Today, the campus spans 60 acres and includes a multi-product, biotech manufacturing and clinical operations complex with six buildings totaling 500,000 square feet. Upon receiving U.S. Food and Drug Administration licensure in 2007, the Oceanside facility added 90,000 liters of capacity that are now approved for the production of Rituxan and Avastin bulk drug substance.

On the Southern California Coast, halfway between Los Angeles and San Diego, Oceanside is a beautiful beachfront community of roughly 200,000 people. As one of Oceanside’s largest employers, Genentech takes great pride in the impact we have on the community, but also in the impact the community has on our employees.

Please view our company video on YouTube:

Connect with us via Social Media:




Key Statistics

Ownership: Subsidiary

Web Site: Genentech
Employees: 10,000+
Symbol: RHHBY



Company News
Genentech (RHHBY) Release: SNP Trace Panel Proves To Be A High-Throughput, Cost-Effective SNP-Based Platform For Profiling Human Tissue And Cell Lines 2/26/2015 9:36:28 AM
Genentech (RHHBY)'s Breast Cancer Cocktail Buys More Than a Year of Life 2/20/2015 6:46:14 AM
Regeneron (REGN)'s Eylea Beats Genentech (RHHBY) in Rare Face Off Over Some Vision Loss Cases 2/19/2015 6:11:14 AM
FDA Grants Genentech (RHHBY)’s Cobimetinib Priority Review For Use In Combination With Zelboraf (Vemurafenib) In Advanced Melanoma 2/19/2015 6:06:45 AM
FDA Approves Genentech (RHHBY)’s Lucentis (Ranibizumab Injection) For Treatment Of Diabetic Retinopathy In People With Diabetic Macular Edema 2/9/2015 5:56:08 AM
Genentech (RHHBY)'s Lucentis Is the First Drug to Win Approval for Diabetic Retinopathy 2/9/2015 5:55:02 AM
Genentech (RHHBY)’s Phase III Study Of Gazyva Showed Significant Benefit In Refractory Indolent Non-Hodgkin’s Lymphoma 2/4/2015 6:08:11 AM
Genentech (RHHBY) Shows Off Positive Phase III Lymphoma Data From Late-Stage Study 2/4/2015 6:07:15 AM
FDA Grants Breakthrough Therapy Designation For Genentech (RHHBY)’s Investigational Cancer Immunotherapy MPDL3280A (Anti-PDL1) In Non-Small Cell Lung Cancer 2/2/2015 6:06:05 AM
Second Breakthrough Status Win for Genentech (RHHBY) Immunotherapy Drug 2/2/2015 6:04:58 AM